- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
King of Prussia Today
By the People, for the People
Phio Pharmaceuticals Secures U.S. Manufacturing Partner for Drug Candidate PH-762
Agreement Marks Key Milestone in Advancing Phio's Skin Cancer Treatment to Next Stage of Clinical Development
Apr. 1, 2026 at 10:23pm
Got story updates? Submit your updates here. ›
Phio Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced a new cGMP drug product manufacturing services agreement with a U.S.-based organization. This partnership will enable Phio to manufacture its lead compound PH-762 for future clinical trials and potential commercial supply as the company works to develop a new treatment for various forms of skin cancer.
Why it matters
Securing a reliable U.S. manufacturing partner is a critical step for Phio as it prepares to advance its PH-762 program into the next stage of clinical development. Having domestic production capabilities will provide strategic advantages and help ensure a smooth transition as Phio seeks regulatory approval and, if successful, commercialization of its novel skin cancer therapy.
The details
Under the new agreement, the U.S. manufacturer will produce Phio's PH-762 compound, an INTASYL-based therapy being evaluated as an intratumoral treatment for cutaneous carcinomas. In Phio's recently completed Phase 1b trial, PH-762 demonstrated a pathological response rate of approximately 65% across five dose-escalation cohorts, with the highest dose cohort seeing an 85% response rate. The company plans to engage with the FDA in the second quarter of 2026 regarding the next stage of clinical development for PH-762.
- Phio's Phase 1b trial of PH-762 enrolled 22 patients across five dose-escalation cohorts.
- Phio has reported no dose-limiting toxicities or serious adverse events in the Phase 1b trial.
- Phio is targeting FDA engagement regarding next-stage clinical development of PH-762 for the second quarter of 2026.
- Phio has projected its current cash and cash equivalents will sustain operations into the first half of 2027.
The players
Phio Pharmaceuticals Corp.
A clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL gene silencing technology to treat various forms of cancer.
PH-762
Phio's lead clinical candidate, an INTASYL compound that silences the PD-1 gene, being evaluated as an intratumoral therapy for cutaneous carcinomas.
Robert Bitterman
President and CEO of Phio Pharmaceuticals.
What they’re saying
“It is a pleasure to partner with an organization known for its quality and expertise in drug product manufacturing services. Further, we value the strategic advantages of working with a U.S. based organization.”
— Robert Bitterman, President and CEO of Phio
What’s next
Phio has indicated that FDA engagement regarding next-stage clinical development of PH-762 is targeted for the second quarter of 2026.
The takeaway
Phio's new manufacturing partnership marks a significant milestone in the advancement of its PH-762 program, providing the company with a reliable U.S.-based source for clinical and potential commercial supply as it prepares to take this novel skin cancer therapy to the next stage of development and regulatory review.
